retatrutide phase2 weight loss is investigational and is not FDA approved. In TRANSCEND-T2D-1, investigators randomized 537 adults with type 2 diabetes inadequately controlled by diet and exercise in a 40-week, double-blind, placebo-controlled phase 3 trial Retatrutide vs Survodutide: 24% vs
Pay in 4 interest-free payments of $7.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5























